ANNOUNCING INDIEBIO SF’S NEXT WAVE – VC-FOUNDER MEETINGS (JUNE 17 TO 21). LEARN MORE

Learn more about investing in EachDay Health

Our team will get back to you soon to follow up on your inquiry.
Opt-In Checkbox
EachDay Health
The future of ADHD treatment is digital.
Founded
2021
Employees*
5
Funding to Date*
$225k
* Data source: Crunchbase
Christian Murphy, CEO
“Eachday is a gamified digital therapeutic that reduces ADHD symptoms in adults and adolescents.”
As of 2020, Adult ADHD impacted 9.34% of the global population, and the average U.S. Adult spends $2,228/year on treatment.

There has been a steady rise in Attention-deficit/hyperactivity disorder (ADHD) patients during the last 20 years with adult diagnosis doubling in the last decade. With up to a 91% heritability, and the fact that ADHD can be brought on by environmental factors, this isn’t a problem that’s going to go away… it’s only going to get worse. 

Eachday is a digital health therapeutic company backed by Carnegie Mellon. Composed of UC Berkeley, Carnegie Mellon, Google Highmark and IDEO alumni, Eachday blends technology with medical and academic excellence to deliver evidence-based support for adolescents and adults with ADHD. 

The company is the first to digitize executive function training, delivered via their self-management app that tracks users’ behaviors and interests, such as task completion, cognitive failures,  and self-reported symptoms, to create a personalized “ADHD Profile.” Then, using data and neuroscience, Eachday provides individualized tools and evidence-based techniques to help users better understand their mind, visualize time, and craft routines that reduce the cognitive burden of completing day-to-day activities and help eliminate ADHD symptoms as they occur. Eachday recently completed their first clinical discovery study and is seeking their seed round to conduct clinical trials.